Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Interferon-Gamma Receptor Signaling Plays an Important Role in Restraining Murine Ovarian Tumor Progression.

Bian G, Leigh ND, Du W, Zhang L, Li L, Cao X.

J Immunol Res Ther. 2016;1(1):15-21.

2.

In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer.

Canese R, Mezzanzanica D, Bagnoli M, Indraccolo S, Canevari S, Podo F, Iorio E.

Front Oncol. 2016 Jun 28;6:164. doi: 10.3389/fonc.2016.00164. Review.

3.

Folic acid-targeted iron oxide nanoparticles as contrast agents for magnetic resonance imaging of human ovarian cancer.

Zhang H, Li J, Hu Y, Shen M, Shi X, Zhang G.

J Ovarian Res. 2016 Mar 29;9:19. doi: 10.1186/s13048-016-0230-2.

4.

Cucurbit [7] uril encapsulated cisplatin overcomes resistance to cisplatin induced by Rab25 overexpression in an intraperitoneal ovarian cancer model.

Gomez-Roman N, McGregor F, Wheate NJ, Plumb JA.

J Ovarian Res. 2015 Sep 18;8:62. doi: 10.1186/s13048-015-0189-4.

5.

MMP-13 In-Vivo Molecular Imaging Reveals Early Expression in Lung Adenocarcinoma.

Salaün M, Peng J, Hensley HH, Roder N, Flieder DB, Houlle-Crépin S, Abramovici-Roels O, Sabourin JC, Thiberville L, Clapper ML.

PLoS One. 2015 Jul 20;10(7):e0132960. doi: 10.1371/journal.pone.0132960.

6.

Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.

Gritsina G, Xiao F, O'Brien SW, Gabbasov R, Maglaty MA, Xu RH, Thapa RJ, Zhou Y, Nicolas E, Litwin S, Balachandran S, Sigal LJ, Huszar D, Connolly DC.

Mol Cancer Ther. 2015 Apr;14(4):1035-47. doi: 10.1158/1535-7163.MCT-14-0800.

7.

Recent technological advances in using mouse models to study ovarian cancer.

House CD, Hernandez L, Annunziata CM.

Front Oncol. 2014 Feb 13;4:26. doi: 10.3389/fonc.2014.00026. Review.

8.

Current status and evolution of preclinical drug development models of epithelial ovarian cancer.

Konstantinopoulos PA, Matulonis UA.

Front Oncol. 2013 Dec 11;3:296. doi: 10.3389/fonc.2013.00296. Review.

9.

STX140, but not paclitaxel, inhibits mammary tumour initiation and progression in C3(1)/SV40 T/t-antigen transgenic mice.

Meyer-Losic F, Newman SP, Day JM, Reed MJ, Kasprzyk PG, Purohit A, Foster PA.

PLoS One. 2013 Dec 6;8(12):e80305. doi: 10.1371/journal.pone.0080305.

10.

Serial orthotopic transplantation of epithelial tumors in single-cell suspension.

McCauley HA, Guasch G.

Methods Mol Biol. 2013;1035:231-45. doi: 10.1007/978-1-62703-508-8_20.

11.

Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.

Liu H, Xiao F, Serebriiskii IG, O'Brien SW, Maglaty MA, Astsaturov I, Litwin S, Martin LP, Proia DA, Golemis EA, Connolly DC.

Clin Cancer Res. 2013 Sep 15;19(18):5053-67. doi: 10.1158/1078-0432.CCR-13-1115.

12.

7,12-dimethylbenz[a]anthracene-induced malignancies in a mouse model of menopause.

Marion SL, Watson J, Sen N, Brewer MA, Barton JK, Hoyer PB.

Comp Med. 2013 Feb;63(1):6-12.

13.

Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.

Nunez-Cruz S, Gimotty PA, Guerra MW, Connolly DC, Wu YQ, DeAngelis RA, Lambris JD, Coukos G, Scholler N.

Neoplasia. 2012 Nov;14(11):994-1004.

14.

Adrenal tumor volume in a genetically engineered mouse model of neuroblastoma determined by magnetic resonance imaging.

Kawano K, Hattori Y, Iwakura H, Akamizu T, Maitani Y.

Exp Ther Med. 2012 Jul;4(1):61-64.

15.

Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice.

Hensley HH, Roder NA, O'Brien SW, Bickel LE, Xiao F, Litwin S, Connolly DC.

Neoplasia. 2012 Jun;14(6):451-62.

16.

Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.

Wu R, Hu TC, Rehemtulla A, Fearon ER, Cho KR.

Clin Cancer Res. 2011 Dec 1;17(23):7359-72. doi: 10.1158/1078-0432.CCR-11-1388.

17.

An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses.

Nunez-Cruz S, Connolly DC, Scholler N.

J Vis Exp. 2010 Nov 28;(45). pii: 2146. doi: 10.3791/2146.

18.

Development of a syngeneic mouse model of epithelial ovarian cancer.

Quinn BA, Xiao F, Bickel L, Martin L, Hua X, Klein-Szanto A, Connolly DC.

J Ovarian Res. 2010 Oct 19;3:24. doi: 10.1186/1757-2215-3-24.

20.

Ovarian cancer mouse models: a summary of current models and their limitations.

Fong MY, Kakar SS.

J Ovarian Res. 2009 Sep 28;2(1):12. doi: 10.1186/1757-2215-2-12.

Supplemental Content

Support Center